# Interactive Brokers Group, Inc. (IBKR)

> Source: Nexqual · https://nexqual.com/IBKR · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Interactive Brokers Group, Inc. (IBKR), nexqual.com/IBKR" · informational, not investment advice.

**Price:** USD 82.28 (-3.57% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 85.33 · day 81.71–85.08 · 52w 58.95–98.75 · market cap $140B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $6.86B, net income $4.90B (71.3% margin) (SEC filings).
- Valuation: P/E 28.6x (avg 5.1x at the last 3 fiscal year-ends).
- 6 of 80 tracked superinvestors hold IBKR (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 1 new, 1 added, 3 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $2.0M; 1 not under a Rule 10b5-1 plan ($2.0M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 6 Form 4 filings, $13K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.18 on a 1–5 scale) (17 analysts), mean target USD 104.66 (range 75–120).
- Total return with dividends: 1Y +23.0% vs S&P 500 +14.9%; 5Y +353.8% vs S&P 500 +80.3%.
- Next earnings: 2026-10-15, EPS estimate USD 0.74, revenue estimate $1.99B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.71B | $3.07B | $4.34B | $5.18B | $6.21B | $6.86B |
| Net income | $1.64B | $1.84B | $2.81B | $3.41B | $4.36B | $4.90B |
| EPS (diluted) | $0.81 | $0.94 | $1.42 | $1.73 | $2.22 | — |
| Net margin | 60.3% | 60.1% | 64.8% | 65.7% | 70.2% | 71.3% |
| Revenue growth | +22.4% | +13.0% | +41.5% | +19.5% | +19.7% | — |
| Cash + short-term investments | $2.40B | $3.44B | $3.75B | $3.63B | $4.96B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 28.6x · P/S 20.4x · P/B 23.7x · Earnings yield 3.49% · Dividend yield (paid, TTM) 0.10%
P/E at fiscal year-ends: Dec 2025 6.6x, Dec 2024 5.7x, Dec 2023 3.1x.

## Superinvestors (SEC 13F-HR, Q2 2026)
6 of 80 tracked investors hold IBKR (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Bryan Lawrence | Oakcliff Capital | 33.42% | $89.7M | Unchanged | Q2 2026 |
| Robert Vinall | RV Capital GmbH | 12.75% | $48.8M | Reduced -26.0% | Q2 2026 |
| William Von Mueffling | Cantillon Capital Management | 6.78% | $45.1M | Reduced -95.4% | Q2 2026 |
| John Armitage | Egerton Capital | 2.75% | $270M | Reduced -23.5% | Q3 2026 |
| Viking Global | Viking Global Investors | 1.20% | $420M | Added +246.5% | Q2 2026 |
| Stephen Mandel | Lone Pine Capital | 0.31% | $50.3M | New position | Q2 2026 |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-04-28 | Harris Lawrence E | Director | 26,000 | $2.0M | 13% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
6 purchases, $13K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-10-01 | Conkling Lori A | Director | 25 | $2K | 85.42 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-01 | Conkling Lori A | Director | 25 | $2K | 94.53 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-03 | Conkling Lori A | Director | 25 | $2K | 87.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Conkling Lori A | Director | 25 | $2K | 88.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Conkling Lori A | Director | 25 | $2K | 86.1 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Conkling Lori A | Director | 25 | $2K | 79.64 | Too little history (no open-market trades in 2023–2025) |

## Analysts
Consensus Buy (mean 2.18 on a 1–5 scale), 17 analysts; mean target USD 104.66 (low 75, high 120).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | Barclays | Target raised | Overweight | $115 → $117 |
| 2026-10-16 | BMO Capital | Target lowered | Outperform | $105 → $100 |
| 2026-10-12 | Evercore ISI Group | Initiated | Outperform | $100 |
| 2026-10-07 | UBS | Target lowered | Neutral | $102 → $101 |
| 2026-10-07 | Barclays | Target raised | Overweight | $114 → $115 |
| 2026-10-06 | BMO Capital | Target lowered | Outperform | $110 → $105 |
| 2026-10-05 | B of A Securities | Target raised | Buy | $114 → $116 |
| 2026-10-02 | Wells Fargo | Initiated | Overweight | $102 |
| 2026-09-02 | Goldman Sachs | Target lowered | Buy | $114 → $113 |
| 2026-08-27 | Raymond James | Initiated | Market Perform |  |
| 2026-07-22 | BMO Capital | Target raised | Outperform | $105 → $110 |
| 2026-07-22 | Barclays | Target raised | Overweight | $108 → $114 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +23.0% | +353.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +23.1% | +35.2% |
| Volatility (annualized) | 39.4% | 33.1% |
| Max drawdown | -18.7% (Feb 2026→Mar 2026) | -37.5% (Feb 2025→Mar 2025) |

## Peers (Capital Markets)
SCHW (Charles Schwab Corporation (The) USD 91.44 -0.22% · HOOD (Robinhood Markets, Inc.) USD 96.58 -5.25% · GS (Goldman Sachs Group, Inc. (The)) USD 891.3 -1.48% · MS (Morgan Stanley) USD 183.97 -1.63% · NMR (Nomura Holdings Inc) USD 9.04 -1.95% · TW (Tradeweb Markets Inc.) USD 121.89 +1.57%

## More
Full page: https://nexqual.com/IBKR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $0.74 | $0.71 | +3.8% | $1.99B | 13 |
| Next quarter (ends 2027-03-31) | $0.77 | $0.71 | +8.6% | $2.09B | 11 |
| Current fiscal year (ends 2026-12-31) | $2.70 | $2.74 | -1.2% | $7.44B | 16 |
| Next fiscal year (ends 2027-12-31) | $3.33 | $3.09 | +7.8% | $8.92B | 17 |